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An ideal vaccine for malaria would target all stages of
the parasite life cycle, and thereby prevent infection,
severe disease and transmission. However, most malar-
iologists agree that if only one stage is to be targeted, it
should be the pre-erythrocytic stage, because induction
of highly protective immune responses against this stage
will prevent blood stage infection and thus disease and
parasite transmission.
Our consortium is working to develop such a vaccine.
The first-generation vaccine is a metabolically active,
non-replicating Plasmodium falciparum sporozoite
(PfSPZ) vaccine that is attenuated by irradiation. The
first major challenge was to manufacture adequate quan-
tities of such a vaccine that met regulatory standards for
initial clinical trials, and demonstrate that it was safe,
well tolerated and immunogenic in humans. This has
been accomplished. The second major challenge is to
determine how to administer for the first time in humans
an unprecedented, non-replicating and metabolically
active (live) whole-organism vaccine formulation com-
posed of PfSPZ that measure 0.5-1.0 μmx7 - 1 0μm, to
induce > 85% protection.
Volunteers immunized by intradermal (ID) or subcu-
taneous (SC) routes were protected in the first clinical
trial. However, the number of protected subjects was
low, and despite a dose response immunogenicity was
sub-optimal. Animal studies show that intravenous (IV)
immunization induces much better immunity and pro-
tection than immunization by the SC or ID routes.
These data have been used to inform the design of the
next clinical trial. Parallel efforts are underway to
optimize non-IV administration of PfSPZ, and the effi-
ciency and scale-up of manufacture.
We are also determining whether genetic targeting
techniques can be used to create a parasite clone that
will produce attenuated PfSPZ that are not only more
potent, but also as safe as radiation-attenuated PfSPZ.
Such PfSPZ could be non-replicating (as are radiation-
attenuated PfSPZ), replication deficient, or replication
competent, but avirulent. Our goal is to develop, license
a n dd e p l o yah i g h l ye f f e c t i v ep r e - e r y t h r o c y t i cs t a g e
PfSPZ vaccine that prevents blood stage infection, dis-
ease, and transmission. Such a vaccine could be used at
the community level in Pf elimination campaigns, and at
the individual level for prevention of Pf malaria in
infants, young children, and pregnant women in ende-
mic areas, as well as individuals of all ages who travel to
malaria-endemic areas.
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